Axsome Therapeutics Inc is trading 4% up today at $256.20 as investors lean into recent positive analyst sentiment and optimism surrounding the company's CNS drug pipeline.
- The move follows a multi-day uptrend supported by new SYMBRAVO migraine data presented in early June.
- Analysts maintain a Buy consensus rating with robust price targets, reflecting confidence in the company's central nervous system (CNS) portfolio despite a lack of fresh headlines on June 11.